COMPASS Pathways plc (NASDAQ:CMPS) Receives Average Rating of “Buy” from Analysts

COMPASS Pathways plc (NASDAQ:CMPS) has been given a consensus recommendation of “Buy” by the six research firms that are presently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $47.40.

A number of equities research analysts have commented on CMPS shares. Royal Bank of Canada started coverage on shares of COMPASS Pathways in a report on Tuesday, July 23rd. They issued an “outperform” rating and a $23.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $120.00 price target on shares of COMPASS Pathways in a report on Friday. Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a report on Friday, June 21st. Finally, Canaccord Genuity Group reduced their price target on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a report on Friday, August 2nd.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Logos Global Management LP grew its holdings in shares of COMPASS Pathways by 349.3% during the second quarter. Logos Global Management LP now owns 1,159,030 shares of the company’s stock valued at $7,001,000 after buying an additional 901,050 shares during the last quarter. Affinity Asset Advisors LLC grew its holdings in shares of COMPASS Pathways by 86.9% during the first quarter. Affinity Asset Advisors LLC now owns 1,027,868 shares of the company’s stock valued at $8,552,000 after buying an additional 477,868 shares during the last quarter. PFM Health Sciences LP grew its holdings in shares of COMPASS Pathways by 540.7% during the fourth quarter. PFM Health Sciences LP now owns 338,761 shares of the company’s stock valued at $2,964,000 after buying an additional 285,890 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of COMPASS Pathways by 1,518.4% during the second quarter. Renaissance Technologies LLC now owns 263,800 shares of the company’s stock valued at $1,593,000 after buying an additional 247,500 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of COMPASS Pathways by 4.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 110,939 shares of the company’s stock valued at $971,000 after buying an additional 4,981 shares during the last quarter. 46.19% of the stock is currently owned by institutional investors and hedge funds.

COMPASS Pathways Price Performance

Shares of NASDAQ CMPS opened at $7.19 on Friday. COMPASS Pathways has a twelve month low of $5.01 and a twelve month high of $12.75. The firm has a fifty day simple moving average of $6.84 and a 200 day simple moving average of $8.28. The company has a market capitalization of $491.66 million, a PE ratio of -3.03 and a beta of 2.27. The company has a quick ratio of 15.23, a current ratio of 15.23 and a debt-to-equity ratio of 0.12.

COMPASS Pathways (NASDAQ:CMPS) last announced its earnings results on Thursday, August 1st. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.03). During the same period last year, the company earned ($0.62) EPS. On average, sell-side analysts forecast that COMPASS Pathways will post -2.24 EPS for the current year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.